JP4332349B2 - ２ｈ−１−ベンゾピラン誘導体、それらの製造法及びそれらの製薬学的組成物 - Google Patents

２ｈ−１−ベンゾピラン誘導体、それらの製造法及びそれらの製薬学的組成物 Download PDF

Info

Publication number
JP4332349B2
JP4332349B2 JP2002559415A JP2002559415A JP4332349B2 JP 4332349 B2 JP4332349 B2 JP 4332349B2 JP 2002559415 A JP2002559415 A JP 2002559415A JP 2002559415 A JP2002559415 A JP 2002559415A JP 4332349 B2 JP4332349 B2 JP 4332349B2
Authority
JP
Japan
Prior art keywords
compound
solution
phenyl
preparation
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002559415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517151A (ja
JP2004517151A5 (enExample
Inventor
デルカナレ，マウリツイオ
アマリ，ガブリーレ
アルマーニ，エリザベタ
チベリ，マウリツイオ
ガルビアテイ，エリザベタ
Original Assignee
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01101521A external-priority patent/EP1229036B1/en
Priority claimed from EP01118682A external-priority patent/EP1281710A1/en
Application filed by キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ filed Critical キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ
Publication of JP2004517151A publication Critical patent/JP2004517151A/ja
Publication of JP2004517151A5 publication Critical patent/JP2004517151A5/ja
Application granted granted Critical
Publication of JP4332349B2 publication Critical patent/JP4332349B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2002559415A 2001-01-24 2002-01-21 ２ｈ−１−ベンゾピラン誘導体、それらの製造法及びそれらの製薬学的組成物 Expired - Fee Related JP4332349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01101521A EP1229036B1 (en) 2001-01-24 2001-01-24 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
EP01118682A EP1281710A1 (en) 2001-08-03 2001-08-03 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
PCT/EP2002/000567 WO2002059113A1 (en) 2001-01-24 2002-01-21 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof

Publications (3)

Publication Number Publication Date
JP2004517151A JP2004517151A (ja) 2004-06-10
JP2004517151A5 JP2004517151A5 (enExample) 2005-12-22
JP4332349B2 true JP4332349B2 (ja) 2009-09-16

Family

ID=26076450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002559415A Expired - Fee Related JP4332349B2 (ja) 2001-01-24 2002-01-21 ２ｈ−１−ベンゾピラン誘導体、それらの製造法及びそれらの製薬学的組成物

Country Status (26)

Country Link
US (1) US6951883B2 (enExample)
EP (1) EP1355906B1 (enExample)
JP (1) JP4332349B2 (enExample)
CN (1) CN1261431C (enExample)
AT (1) ATE286894T1 (enExample)
AU (1) AU2002237282B2 (enExample)
BR (1) BR0207066A (enExample)
CA (1) CA2435775A1 (enExample)
CZ (1) CZ20032014A3 (enExample)
DE (1) DE60202590T2 (enExample)
DK (1) DK1355906T3 (enExample)
DZ (1) DZ3459A1 (enExample)
EA (1) EA006158B1 (enExample)
ES (1) ES2236485T3 (enExample)
HU (1) HUP0401018A3 (enExample)
IL (2) IL157065A0 (enExample)
MA (1) MA26982A1 (enExample)
MX (1) MXPA03006505A (enExample)
NO (1) NO327808B1 (enExample)
NZ (1) NZ527144A (enExample)
PL (1) PL365062A1 (enExample)
PT (1) PT1355906E (enExample)
SI (1) SI1355906T1 (enExample)
SK (1) SK287086B6 (enExample)
TN (1) TNSN03043A1 (enExample)
WO (1) WO2002059113A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
NZ553834A (en) * 2004-09-21 2010-03-26 Novogen Res Pty Ltd 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives
EP1809618B1 (en) * 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
AU2005201855B2 (en) * 2004-09-21 2012-03-29 Marshall Edwards, Inc. Chroman derived compounds and formulations thereof for use in therapy
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
CN101444499B (zh) * 2007-11-26 2012-12-05 湘北威尔曼制药股份有限公司 一种化合物及其组合物的新用途
ES2773732T3 (es) 2010-11-01 2020-07-14 Mei Pharma Inc Composiciones de isoflavonoides y procedimientos para el tratamiento del cáncer
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
CN109963848B (zh) * 2016-11-17 2022-07-05 赛诺菲 取代的n-(3-氟丙基)-吡咯烷化合物、其制备方法以及其治疗用途
US20200215025A1 (en) * 2017-09-15 2020-07-09 Norbio No. 1 Pty Ltd Treatment of excitotoxicity
CN112225716A (zh) * 2020-10-30 2021-01-15 陕西嘉禾生物科技股份有限公司 一种鹰嘴豆牙素a的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374245A (en) * 1964-04-01 1968-03-19 Ciba Geigy Corp Unsaturated oxacycles
DE1518002C3 (de) * 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
CA2269936A1 (en) * 1996-10-28 1998-05-07 Lise Brown Christiansen Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP3251946B2 (ja) * 1996-12-13 2002-01-28 中外製薬株式会社 新規なベンゾピラン誘導体
KR20000001793A (ko) 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
WO2000039120A2 (en) 1998-12-30 2000-07-06 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors

Also Published As

Publication number Publication date
EP1355906A1 (en) 2003-10-29
DZ3459A1 (fr) 2002-08-01
CN1261431C (zh) 2006-06-28
PT1355906E (pt) 2005-05-31
NO20033318L (no) 2003-09-24
DE60202590T2 (de) 2005-12-29
US20040106595A1 (en) 2004-06-03
CN1487934A (zh) 2004-04-07
NZ527144A (en) 2005-03-24
TNSN03043A1 (en) 2005-12-23
SK287086B6 (sk) 2009-11-05
NO327808B1 (no) 2009-09-28
IL157065A0 (en) 2004-02-08
SK9392003A3 (en) 2003-12-02
EP1355906B1 (en) 2005-01-12
JP2004517151A (ja) 2004-06-10
AU2002237282B2 (en) 2007-02-15
WO2002059113A1 (en) 2002-08-01
ES2236485T3 (es) 2005-07-16
HK1060558A1 (en) 2004-08-13
EA200300727A1 (ru) 2004-02-26
HUP0401018A2 (hu) 2004-09-28
NO20033318D0 (no) 2003-07-23
EA006158B1 (ru) 2005-10-27
IL157065A (en) 2010-05-17
DK1355906T3 (da) 2005-05-30
US6951883B2 (en) 2005-10-04
CA2435775A1 (en) 2002-08-01
MXPA03006505A (es) 2004-04-21
BR0207066A (pt) 2004-03-30
CZ20032014A3 (cs) 2003-12-17
DE60202590D1 (de) 2005-02-17
ATE286894T1 (de) 2005-01-15
HUP0401018A3 (en) 2007-05-29
PL365062A1 (en) 2004-12-27
MA26982A1 (fr) 2004-12-20
SI1355906T1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
US5472962A (en) Benzothiophene derivative
JP4332349B2 (ja) ２ｈ−１−ベンゾピラン誘導体、それらの製造法及びそれらの製薬学的組成物
AU781282B2 (en) Compounds and methods for modulation of estrogen receptors
JP2661699B2 (ja) ピペリジンオピオイド拮抗剤
CA2729217C (en) 6-substituted phenoxychroman carboxylic acid derivatives
JPH06507615A (ja) ２−フェニルベンゾ［ｂ］フランおよび−チオフェン、それらの製造法および該化合物を含有する、抗エストロゲン作用を有する製薬学的調製剤
US6159971A (en) Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist
US6844336B2 (en) 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity
US6387899B1 (en) Substituted chroman derivatives
AU2002237282A1 (en) 2H-1-Benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
KR900007781B1 (ko) 융합된 벤즈아제핀
JP2004527516A (ja) ピペラジン誘導体、それらの製造方法および治療における使用（５ｈｔ１ｂ受容体活性）
EP1229036A1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
Gauthier et al. Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution
US6599921B2 (en) Non-steroidal estrogen receptor ligands
HK1060558B (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
HUP0204084A2 (hu) Új heteroarilszármazékok, eljárás előállításukra és alkalmazásuk
EP1281710A1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
JPH10109966A5 (enExample)
JP2007516155A (ja) エストロゲン活性を有する（３ｒ，４ｒ）−トランス−３，４−ジアリールクロマン誘導体
CZ2000948A3 (cs) Substituované chromanové deriváty
HK1155735B (en) 6-substituted phenoxychroman carboxylic acid derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050120

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20081029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090616

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090622

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120626

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees